Positive and negative effects of thalidomide on refractory cutaneous lupus erythematosus

References

• Karim MY, Ruiz-Irastorza G, Khamashta MA, Hughes GR. Update on therapy-thalidomide in the treatment of lupus. Lupus 2001; 10: 188–192
   PubMed Web of Science ®Google Scholar
• Tseng S, Pak G, Washenik K, Pomeranz MK, Shupack JL. Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol 1996; 35: 969–979
   PubMed Web of Science ®Google Scholar
• Zampieri S, Alaibac M, Iaccarino L, Rondinone R, Ghirardello A, Sarzi-Puttini P, Peserico A, Doria A. TNF-α is expressed in refractory skin lesions from subacute cutaneous lupus erythematosus patients. Ann Rheum Dis 2005; in press.
   Google Scholar
• Sheskin J. The treatment of lepra reaction in lepromatosus leprosy. Fifteen years' experience with thalidomide. Int J Dermatol 1980; 19: 318–322
   PubMed Web of Science ®Google Scholar
• Wulff CH, Hoyer H, Asboc-Hansen G, Brodthagen H. Development of polyneuropathy during thalidomide therapy. Br J Dermatol 1985; 112: 475–480
   PubMed Web of Science ®Google Scholar
• Knop J, Bonsmann G, Happle R, et al. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. Br J Dermatol 1983; 108: 461–466
   PubMed Web of Science ®Google Scholar
• Bastuji-Garin S, Ochonisky S, Bouche P, et al. Incidence and risk factors for thalidomide neuropathy: A prospective study of 135 dermatologic patients. J Investig Dermatol 2002; 119: 1020–1026
   PubMed Web of Science ®Google Scholar
• Fullerton PM, O'Sullivan J. Thalidomide neuropathy; a clinical, electrophysiological, and histological follow-up study. J Neurol Neurosurg Psychiat 1968; 31: 543–551
   PubMed Web of Science ®Google Scholar
• Calabrese L, Fleischer AB, Jr. Thalidomide: Current and potential clinical applications. Am J Med 2000; 108: 487–495
   PubMed Web of Science ®Google Scholar
• Chaudhry V, Cornblath DR, Corse A, et al. Thalidomide-induced neuropathy. Neurology 2002; 59: 1872–1875
   PubMed Web of Science ®Google Scholar
• Gardner-Medwin JMM, Smith NJ, Powell RJ. Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet's disease: Use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis 1994; 53: 828–832
   PubMed Web of Science ®Google Scholar
• Ochonisky S, Verroust J, Bastuji-Garin S, Gherardi R, Revuz J. Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients. Arch Dermatol 1994; 130: 66–69
   PubMed Web of Science ®Google Scholar
• Chaudhry V, Chaudhry M, Crawford TO, Simmons-O'Brien E, Griffin JW. Toxic neuropathy in patients with pre-existing neuropathy. Neurology 2003; 60: 337–340
   PubMed Web of Science ®Google Scholar
• Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–1277
   PubMed Web of Science ®Google Scholar
• American Rheumatism Association Glossary Committee. Dictionary of the rheumatic disease: Signs and symptoms. Conctact Associates International, Bayport, New York 1982; Vol. 1: 1–80, 1st edn.
   Google Scholar
• Harris EN. Antiphospholipid antibodies. Br J Haematol 1990; 74: 1–9
   PubMed Web of Science ®Google Scholar
• Vitali C, Bencivelli W, Isenberg DA, et al. Disease activity in systemic lupus erythematosus: Report of the Consensus Study Group of the European Workshop for Rheumatology Research. II Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 1992; 10: 541–547
   PubMedGoogle Scholar
• Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363–369
   PubMed Web of Science ®Google Scholar
• Dyck PJ. Detection, characterization, and staging of polyneuropathy: Assessed in diabetics. Muscle Nerve 1988; 11: 21–32
   PubMed Web of Science ®Google Scholar
• Notermans NC, Wokke JH, Lokhorst HM, Franssen H, van der Graaf Y, Jennekens FG. Polyneuropathy associated with monoclonal gammopathy of undetermined significance. A prospective study of the prognostic value of clinical and laboratory abnormalities. Brain 1994; 117: 1385–1393
   PubMed Web of Science ®Google Scholar
• van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988; 19: 604–607
   PubMed Web of Science ®Google Scholar
• Rinaldi S, Doria A, Salaffi F, Ermani M, Iaccarino L, Ghirardello A, Zampieri S, Gambari PF, Perini G. Health-related quality of life in Italian patients with systemic lupus erythematosus. I. Relationship between physical and mental dimension and impact of age. Rheumatology 2004; 43: 1574–1579
   PubMed Web of Science ®Google Scholar
• Doria A, Rinaldi S, Ermani M, Salaffi F, Iaccarino L, Ghirardello A, Zampieri S, Della Libera S, Perini G, Todesco S. Health-related quality of life in Italian patients with systemic lupus erythematosus. II. Role of clinical, immunological, and psychological determinants. Rheumatology 2004; 43: 1580–1586
   PubMed Web of Science ®Google Scholar
• Housman TS, Jorizzo JL, McCarty MA, Grummer SE, Fleischer AB, Jr, Sutej PG. Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus. Arch Dermatol 2003; 139: 50–54
   PubMedGoogle Scholar
• Lagueny A, Rommel A, Vignolly B, et al. Thalidomide neuropathy: An electrophysiologic study. Muscle Nerve 1986; 9: 837–844
   PubMed Web of Science ®Google Scholar
• Clemmensen OJ, Olsen PZ, Andersen KE. Thalidomide neurotoxicity. Arch Dermatol 1984; 120: 338–341
   PubMed Web of Science ®Google Scholar
• Giannini F, Volpi N, Rossi S, Passero S, Fimiani M, Cerase A. Thalidomide-induced neuropathy: A ganglionopathy?. Neurology 2003; 60: 877–878
   PubMed Web of Science ®Google Scholar
• Hess CW, Hunziker T, Kupfer A, Ludin HP. Thalidomide-induced peripheral neuropathy. A prospective clinical, neurophysiological and pharmacogenetic evaluation. J Neurol 1986; 233: 83–89
   PubMed Web of Science ®Google Scholar
• Harland CC, Steventon GB, Marsden JR. Thalidomide-induced neuropathy and genetic differences in drug metabolism. Eur J Clin Pharmacol 1995; 49: 1–6
   PubMed Web of Science ®Google Scholar
• Hamanoue M, Middleton G, Wyatt S, Jaffray E, Hay RT, Davies AM. p75-mediated NF-kappaB activation enhances the survival response of developing sensory neurons to nerve growth factor. Mol Cell Neurosci 1999; 14: 28–40
   PubMed Web of Science ®Google Scholar
• Flageul B, Wallach D, Cavelier-Balloy B, Bachelez H, Carsuzaa F, Dubertret L. Thalidomide and Thrombosis. Ann Dermatol Venereol 2000; 127: 171–174
   PubMed Web of Science ®Google Scholar
• Ghirardello A, Doria A, Ruffatti A, et al. Antiphospholipid antibodies (aPL) in systemic lupus erythematosus (SLE). Are they specific tools for the diagnosis of aPL syndrome in SLE?. Ann Rheum Dis 1994; 53: 40–42
   Google Scholar
• Doria A, Ghirardello A, Boscaro M, et al. Fibrinolysis and coagulation abnormalities in systemic lupus erythematosus. Relationship with Raynaud's phenomenon, disease activity, inflammatory indices, anticardiolipin antibodies and corticosteroid therapy. Rheumatol Int 1995; 14: 207–211
   PubMedGoogle Scholar
• Piette J-C, Sbaï A, Francès C. Warning: Thalidomide-related thrombotic risk potentially concerns patients with lupus. Lupus 2002; 11: 67–70
   PubMed Web of Science ®Google Scholar